Assessment of pharmacogenomic agreement
نویسندگان
چکیده
In 2013 we published an analysis demonstrating that drug response data and gene-drug associations reported in two independent large-scale pharmacogenomic screens, Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE), were inconsistent. The GDSC and CCLE investigators recently reported that their respective studies exhibit reasonable agreement and yield similar molecular predictors of drug response, seemingly contradicting our previous findings. Reanalyzing the authors' published methods and results, we found that their analysis failed to account for variability in the genomic data and more importantly compared different drug sensitivity measures from each study, which substantially deviate from our more stringent consistency assessment. Our comparison of the most updated genomic and pharmacological data from the GDSC and CCLE confirms our published findings that the measures of drug response reported by these two groups are not consistent. We believe that a principled approach to assess the reproducibility of drug sensitivity predictors is necessary before envisioning their translation into clinical settings.
منابع مشابه
Health care professionals' perceptions of the role of pharmacogenomic data.
OBJECTIVE To explore the perceptions of health care professionals in examining the uses of pharmacogenomic data. METHODS A mailed questionnaire elicited respondent perceptions of how the use of pharmacogenomic information would impact the provision of health-related services (7-point scale: 7=strongly increase to 1=strongly decrease). Respondents were also asked to describe their level of agr...
متن کاملKnowledge and attitudes of oncology nurses regarding pharmacogenomic testing.
More than 20 different pharmacogenomic tests are being used in the oncology field. The current descriptive study was conducted with 368 oncology nurses in North Carolina to identify and test key elements of Rogers' Diffusion of Innovation Theory that play a role in the adoption of pharmacogenomic testing. Oncology nurses who participated in this study had limited knowledge of genomics and pharm...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملPharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
Many clinical trials of oncology drugs now include at least a consideration of pharmacogenomics, the study of germline or acquired genetic factors governing a drug's response and toxicity. Besides the potential benefit to patients from the consideration of personalized pharmacogenomic information when making treatment decisions, the incentive is clear for oncology drug developers to incorporate...
متن کاملTest-Retest and Inter-Rater Reliability Study of the Schedule for Oral-Motor Assessment in Persian Children
Objectives: Reliable and valid clinical tools to screen, diagnose, and describe eating functions and dysphagia in children are highly warranted. Today most specialists are aware of the role of assessment scales in the treatment of affected individuals. However, the problem is that the clinical tools used might be nonstandard, and worldwide, there is no integrated assessment performed to assess ...
متن کامل